| Today’s Big NewsOct 28, 2024 |
| By Nick Paul Taylor AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The buyout will give AbbVie control of an Alzheimer’s disease drug candidate that Aliada in-licensed from Johnson & Johnson to try to improve on the first generation of anti-amyloid-beta antibodies. |
|
|
|
By Darren Incorvaia Don’t stop Monte Rosa Therapeutics now. The Boston-based biotech is having a ball after signing a deal with Novartis to the tune of $150 million for a molecular glue degrader, developed using the company’s QuEEN platform, that makes an autoimmune-disease-causing protein bite the dust. |
By Nick Paul Taylor Vera Therapeutics has shown the effect of atacicept on kidney function in patients with immunoglobulin A nephropathy persists out to 96 weeks. The durability of the effects seen in the phase 2b trial led Evercore ISI analysts to say “this feels like a ‘functional cure.'” |
Sponsored by Questex Fierce Biotech sits down with digital marketing leaders to discuss this year's most innovative topics at Fierce Biotech Summit and New Product Planning |
|
| 45 markers for cytokine signaling/inflammationTrust RBM for Olink, Luminex & Simoa immunoassays
|
|
By Kevin Dunleavy While other companies gave up on their attempts to develop a non-opioid pain relief medicine by targeting sodium channel inhibition, Vertex remained confident in its ability to find an answer and is now on the verge of gaining approval for the first significant innovation in the indication in more than two decades. |
Sponsored by Turbine.Ai Join us on the latest Top Line podcast as we dive into how Turbine Simulated Cell Technologies is reshaping drug development. Discover their innovative approaches to combatting biases in data, leading to more effective cancer treatments. Tune in now! |
By Zoey Becker The company has stepped out of stealth with a potential Keytruda rival and a stacked leadership team that includes Seagen's former CEO David Epstein and Boehringer vet Mehdi Shahidi, M.D. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Darren Incorvaia Yet another CRO giant has taken a revenue hit due to a customer demand dip. Icon reported third-quarter revenue of $2.03 billion, underperforming analyst expectations of $2.142 billion. |
By Nick Paul Taylor The fog has lifted to reveal a rebranded biotech: Parabilis Medicines. Formerly called FogPharma, the biotech picked its new name to reflect its focus on expanding what is possible in the treatment of serious diseases and commitment to ensuring its medicines reach patients globally. |
By Darren Incorvaia While cryptosporidiosis, infection by the protist parasite Cryptosporidium, is rare in the U.S., it is a common cause of deadly diarrhea in other parts of the world. The only FDA-approved treatment for the infection, nitazoxanide, doesn’t work well in immunocompromised and malnourished children, the group most vulnerable to the pathogen. This has led to cryptosporidiosis being called a “truly neglected tropical disease.” |
By Fraiser Kansteiner Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy. While Apellis' drug seems to have an efficacy edge based on a cross-trial comparison, Novartis may have gotten the jump by filing for approvals ahead of its competitor. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs. |
|
|---|
|
|
|
Wednesday, November 6, 2024 | 1pm ET / 10am PT Generative AI models help scientists better understand proteins, small molecules, DNA, biomedical text, and more. But building, training, and deploying these models can be complex. Join us to discuss the benefits of moving to the cloud to accelerate drug discovery pipelines, and why using customized AI models can help you get to market faster. Register now.
|
|
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
| eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
